A5102993155- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Screening and Detection
- Colorectal and Anal Carcinomas
- Multiple and Secondary Primary Cancers
- Colorectal Cancer Surgical Treatments
- Gastric Cancer Management and Outcomes
- Intraperitoneal and Appendiceal Malignancies
- Radiomics and Machine Learning in Medical Imaging
- Nutrition and Health in Aging
- Cancer Immunotherapy and Biomarkers
- Inflammatory Biomarkers in Disease Prognosis
- Renal cell carcinoma treatment
- Gastrointestinal Tumor Research and Treatment
- Frailty in Older Adults
- Genetics, Bioinformatics, and Biomedical Research
- Metastasis and carcinoma case studies
- Molecular Biology Techniques and Applications
- Stoma care and complications
- Ovarian cancer diagnosis and treatment
West Virginia University
2017-2025
The Ohio State University
2013-2019
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2013-2016
The Ohio State University Wexner Medical Center
2013
Scottsdale Community College
2000
Iowa Oncology Research Association
2000
Missouri Valley Cancer Consortium
2000
University of Nebraska Medical Center
2000
Creighton University
2000
Rapid City Regional Hospital
2000
Lynch syndrome, caused by germline mutations in the mismatch repair genes, is associated with increased cancer risk. Here using a large whole-genome sequencing data bank, registry and colorectal tumour bank we determine prevalence of risks pathogenicity several variants Icelandic population. We use samples from 1,182 patients diagnosed between 2000-2009. One-hundred thirty-two (11.2%) tumours are deficient per immunohistochemistry. Twenty-one (1.8%) have syndrome while 106 (9.0%) somatic...
192 Background: An exploratory analysis of a randomized phase II study in HCC comparing doxorubicin (D) alone to plus sorafenib (D+S) showed significant improvement overall survival favoring D+S (JAMA, 2011). The results appeared promising compared the historic outcomes seen pivotal (S) trials. CALGB 80802 was designed determine if improved S alone. Methods: Patients with histologically proven advanced HCC, no prior systemic therapy and Child-Pugh A were receive D 60 mg/m 2 every 21 days 400...
To determine the frequency and prognostic association of molecular markers by anatomic tumor site in patients with stage III colon carcinomas.In a randomized trial adjuvant FOLFOX ± cetuximab, BRAF(V600E) KRAS (exon 2) mutations DNA mismatch repair (MMR) proteins were analyzed tumors (N = 3,018) relationship to location, including subsite. Cox models used assess clinical outcome, overall survival (OS).KRAS codon 12 most frequent at splenic flexure cecum; 13 evenly distributed. BRAF mutation...
Irinotecan is cytotoxic in patients with advanced colorectal cancer (CRC). SN-38 (10-hydroxy-7-ethyl-camptothecin) the active metabolite of irinotecan. Attachment polyethylene glycol (PEG) polymer chains (pegylation) to (EZN-2208) increases solubility, exposure, and half-life SN-38. Preclinical studies demonstrated superior vitro efficacy EZN-2208 when it was tested irinotecan-refractory human CRC cell lines.Patients metastatic or locally recurrent who had previously received 5-flurouracil...
90 Background: Appendiceal adenocarcinoma incidence rates are increasing across all age groups, sexes and histological subtypes in the United States. Birth cohort patterns of appendiceal adenocarcinomas can provide us with new, etiologic clues into these rising but have not been examined for this rare malignant tumor type. We estimated birth cohorts Methods: Using National Cancer Institute’s Surveillance, Epidemiology, End Results (SEER) Program data from eight population-based cancer...
819 Background: Incidence rates of rare appendiceal cancers are increasing across the United States. Although this is suggestive a growing population cancer survivors over time, risk second primary specific to patients with first adenocarcinoma remains unknown. Methods: We conducted population-based study adults (age ≥18 years) diagnosed from 1992 2021, using data Surveillance, Epidemiology, and End Results (SEER) Program. estimated cumulative incidence cancer, defined as any at least 3...
4003 Background: An exploratory analysis of a randomized phase II study in HCC comparing doxorubicin (D) alone to plus sorafenib (D+S) showed significant improvement overall survival favoring D+S (JAMA, 2011). The results appeared promising compared the historic outcomes seen pivotal (S) trials. CALGB 80802 was designed determine if improved S alone. Methods: Patients with histologically proven advanced HCC, no prior systemic therapy and Child-Pugh A were receive D 60 mg/m2 every 21 days 400...
366 Background: The combination of gemcitabine and nab-paclitaxel (GA) in first line treatment (tx) MPC has a modest survival advantage over (gem) alone, but adds significant toxicities (tox) increased cost. Based on data suggesting that biweekly administration (adm) gem-based combinations preserves efficacy improves tox profile, our institution adopted modified regimen GA (mGA). Methods: This is retrospective analysis prospectively maintained database patients (pts) with pancreatic cancer...
Abstract Defining molecular features that can predict the recurrence of colorectal cancer (CRC) for stage II-III patients remains challenging in research. Most available clinical samples are Formalin-Fixed, Paraffin-Embedded (FFPE). NanoString nCounter ® and Affymetrix GeneChip Human Transcriptome Array 2.0 (HTA) two platforms marketed high-throughput gene expression profiling FFPE samples. In this study, to evaluate frozen tissue-derived prognostic signatures CRC samples, we evaluated 516...
275 Background: FOLFIRINOX exhibits a meaningful improvement in outcome measures metastatic pancreatic cancer, making it an interesting regimen for BRPC and LAURPC. However, its use remains prohibitive due to toxicity. In this study, we examine the outcomes of mFOLFIRINOX as neoadjuvant strategy patients with Methods: This is retrospective analysis prospectively maintained database who received or LAURPC at Ohio State University. follows: irinotecan 165 mg/m 2 ; oxaliplatin 85 5-fluorouracil...
Abstract Background Inflammation and insufficient physical inactivity contribute to individual-level risk of disease recurrence death in stage III colon cancer. The extent which increased inflammatory can be offset by sufficient activity remains unknown. Methods This cohort study was nested within the Cancer Leukemia Group B (now part Alliance for Clinical Trials Oncology) Southwest Oncology randomized trial. Inflammatory burden quantified high-sensitivity C-reactive protein, interleukin-6,...
3579 Background: Tumor infiltrating lymphocytes (TIL) indicate a host immune response that may influence survival. Immunoscore was developed using CD3 + and CD8 density location in primary CC pts with pooled stages, varying treatment follow-up. We determined if individual markers and/or are prognostic resected stage III (N=600). Methods: T-cell or CD20 B lymphocyte central tumor (CT) invasive margin (IM) evaluated by immunostaining quantified image analysis. calculated on scale of I0 to I4...
Multiplex somatic testing has emerged as a strategy to test patients with advanced cancer. We demonstrate our analytic validation approach for gene hotspot panel and real-time prospective clinical application any cancer type. The TruSight Tumor 26 assay amplifies 85 regions across genes. Using cell line tumor mixes, we observed that 100% of the 14,715 targeted bases had at least 1000x raw coverage. determined sensitivity (100%, 95% CI: 96-100%), positive predictive value reproducibility...
614 Background: A consensus interpretation of the IDEA colon cancer study results suggested that risk categories based on T/N stage grouping be used to guide decision-making for duration (3 vs 6 months) adjuvant FOLFOX or CapeOX chemotherapy. Given prognostic potential immune biomarkers, we examined immunoscore and individual T B lymphocyte markers in low high subsets III carcinoma patients (N=600) treated with FOLFOX. Methods: Immunoscore (CD3 + , CD8 ) T-cell CD20 B-cell immunostain...
60 Background: DDR mutations are associated with higher neoantigen load and tumor infiltrating lymphocytes, a potential biomarker for immunotherapy. We investigated the association of in gastric (GC), esophageal (EC), gastroesophageal junction (GEJ) cancers MSI, PD-L1, TMB, known predictors immune checkpoint inhibitors. Methods: 20 were tested by Next-Generation Sequencing (NGS) 592-gene panel on total 1935 (709 EC; 831 GC; 355 GEJ) cancers. TMB was assessed NGS, MSI NGS or fragment...
// Sameh Mikhail 1 , Kristen Ciombor Anne Noonan Christina Wu Richard Goldberg Weiqiang Zhao 2 Lai Wei 3 Kristina Mathey Melissa Yereb Cynthia Timmers Tanios Bekaii-Saab Department of Medicine, The Ohio State University Comprehensive Cancer Center-James Hospital and Solove Research Institute, Columbus, 43221, USA Pathology, Biostatistics, Correspondence to: Mikhail, e-mail: sameh.mikhail@osumc.edu Keywords: next generation sequencing, gastro-esophageal cancer, molecular profiling, c-MET,...
At present there remains a need for more effective systemic therapy in advanced pancreatic cancer. Some studies have suggested that infusional chemotherapy schedules and biomodulation of 5-fluorouracil (5-FU) may improve the therapeutic outcome colon One such regimen uses continuous infusion 5-FU, weekly leucovorin, daily dipyridamole, intermittent mitomycin-C has activity both unresectable carcinoma. The intent this trial was to test effectiveness four-drug Patients received 5-FU 200 mg/m2...
TPS3633 Background: Patients with mCRC who fail 2 or 3 lines of treatment have few effective options. MIF is dramatically upregulated in CRC tissue and its serum concentration positively correlates increased tumor aggressiveness risk hepatic metastasis pts. appears to contribute cancer progression tumor-associated anti-apoptosis, angiogenic growth factor expression, neovascularization hypoxic adaptation. Imalumab a novel recombinant, fully-human, monoclonal antibody specific for the...